NanoPharmaceuticals Logo

About Us

Senior Management and Board of Directors

James Lynch, PhD, MBA
Chief Executive Officer, Member of the Board of Directors for NanoPharmaceuticals

Dr. Lynch has a 35-year pharmaceutical industry career with experience in Big Pharma and start-up companies, as well as management consulting and organizational development.

Dr. Lynch began his career at Novartis Pharmaceuticals—formerly, Sandoz—with roles in Quality Assurance, Research and Development (R&D), Strategic Marketing, and Medical Affairs. In his first multi-functional role in New Product Management, he was responsible for guiding drug development teams made up of commercial, clinical, regulatory, manufacturing and medicinal chemistry components. He assessed commercial potential of pipeline drugs. This included defining target profiles, financial forecasts, market assessments and competitive risks that underlie the basis for funding and business development decisions.

Dr. Lynch subsequently assumed the role of management consultant in the technology practice of the PA Consulting Group, a United Kingdom-based consulting firm, where he directed global projects for major PA clients. These included Pfizer and Mallinckrodt Imaging Inc. and responsibilities at these firms for R&D Acceleration.

Other positions held by Dr. Lynch included service as Associate Director for Business Development and Strategic Planning at Hoffman-La Roche and Senior Director for Business Development at Quintiles. Among the start-up companies in which he has been substantially involved is Reliant Pharmaceuticals. The latter matured from 8 to more than 500 employees and was acquired by GSK for $1.6 billion.

Dr. Lynch earned a BS degree in Chemistry at Siena College, a PhD in Inorganic/Analytical Chemistry at Seton Hall University, and an Executive MBA at Columbia University. The latter academic experience was sponsored by Sandoz. Dr. Lynch is a volunteer member of the Crohn’s & Colitis Foundation Industry Working Group, for which responsibilities include guidance of investments and connections across the pharmaceutical industry.

Shaker A. Mousa, PhD, MBA, FACC, FACB, FNAI
Founder and Executive Vice President of Drug Discovery and Drug Development

Prior to transitioning to academia as a Professor of Pharmacology, Executive Vice President, Vice Provost of Research, Dr. Mousa held a senior, principal research scientist and a research fellow position at DuPont Pharmaceuticals and Imaging Co., DuPont Merck, and DuPont Pharmaceuticals Company for two decades. Among Dr. Mousa’s professional accomplishments are his contributions to patents related to the discovery and development of FDA-approved products. He contributed to the discovery of novel anti-platelet, anti-thrombotic therapies, ultra-short acting cardio selective beta-adrenergic receptor blockers, noninvasive myocardial perfusion and thrombus imaging agents. His work is reported in over 1,000 peer-reviewed publications and he holds over 400 US and International Patents. In 2002, he founded state of the art Pharmaceutical Research Institute (PRI) focusing on translational research in Drug Discovery and Drug Development. The Institute utilized various forms of enabling technologies ranging from biotechnology, nanotechnology, stem cells, drug design, high throughput screening, formulation, drug delivery, and the study of pharmacokinetics, pharmacodynamics, and pharmacogenomics.

Dr. Mousa received a Ph.D. in Pharmacology from Ohio State University, completed his post-doctoral research in Cardiovascular Pharmacology at the University of Kentucky in Lexington, and earned his MBA from Widener University in Chester, Pennsylvania. He is a Fellow of the American College of Cardiology (FACC), a Fellow of the National Academy of Clinical Biochemistry (FACB), a Fellow of the American Heart Association (FAHA), and a Fellow of the National Academy of Inventors (FNAI). He is a member of several national and international societies and serves on several study sections of NIH, DOD, and other funding agencies. In addition, he is an editor-in-chief and serves on the editorial boards and as a reviewer for several high impact scientific and medical journals.

Paul J. Davis, MD, MACP
Founder, Executive Vice President and Chief Scientific Officer

Paul J. Davis, MD, MACP is Professor of Medicine, Albany Medical College, Albany, NY and Adjunct Professor of Pharmacy, Albany College of Pharmacy and Health Sciences. He is also Executive Vice President and Chief Scientific Officer at NanoPharmaceuticals LLC. He obtained his MD degree at Harvard Medical School, had his medical residency training at Albert Einstein College of Medicine in New York City and his endocrine training at the NIH. He has served on the medical faculties of Johns Hopkins University, the University at Buffalo and Albany Medical College. He was Department of Medicine Chair at Albany for ten years. He has been a member of 12 U.S. Department of Veterans Affairs research and clinical committees in Washington, DC, has served on multiple NIH committees and was a member for six years of the Extramural Review Panel of the Chernobyl Tissue Bank of the European Union. He has co-authored 300 research publications—largely dealing with the molecular bases of the actions of thyroid hormone—and has co-edited 4 scientific textbooks. He holds and is co-inventor of over 40 patents. He has served as Editor of two scientific journals, is currently on the editorial boards of five journals and is a subspecialty Editor of Faculty Opinions: Diabetes & Endocrinology (formerly, Faculty of 1000). He has served in nationally elected offices of the American Board of Internal Medicine, the American College of Physicians, and the American Thyroid Association. With Dr. Shaker A. Mousa, he co-discovered the cell surface receptor for thyroid hormone analogues and co-founded NanoPharmaceuticals LLC.

Michael Rosenthal was a founder and former CEO of NanoPharmaceuticals. His leadership and contribution to the Company will forever be remembered and appreciated.